[The cellular immunity indices of patients with malignant melanoma using the viral immunomodulator rigvir].
The effect of rigvir, an immunomodulator of the viral origin, on cell-mediated immunity was studied in patients with skin malignant melanoma. Rosette formation and monoclonal antibody techniques were used to measure blood immunocompetent cell levels in patients with the above pathology, cases of benign skin tumors and healthy subjects. Rigvir was shown to influence natural resistance by raising blood monocyte and large granule-containing lymphocyte levels. It potentiated recruitment of pre-T-lymphocytes and young active T-lymphocytes to the peripheral blood.
Glinkina
L S
LS
Bruvere
R Zh
RZh
Venskus
D R
DR
Garklava
R R
RR
Muceniece
A J
AJ
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D004341:Drug Evaluation; D029822:Enterovirus B, Human / Q000276:immunology*; D005260:Female; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000276:immunology; D008875:Middle Aged; D012397:Rosette Formation; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology; D013997:Time Factors
D000276:Adjuvants, Immunologic
Pokazateli kletochnogo immuniteta u bol'nykh zlokachestvennoĭ melanomoĭ pri primenenii virusnogo immunomoduliatora rigvira.